Progenics Pharmaceuticals (PGNX) Ends Hepatitis C Program PRO 206
Up)
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the discontinuation of development for PRO 206, a pre-clinical compound for the treatment of hepatitis C virus (HCV) infection.
Progenics said the decision was made as part of a portfolio review, and is in line with the Company's ongoing initiative to allocate resources to the most important programs in order to increase its operating efficiencies. The Company will instead focus on its second-generation HCV-entry inhibitor portfolio and anticipates selection of a new development candidate in 2010.
Progenics said the decision was made as part of a portfolio review, and is in line with the Company's ongoing initiative to allocate resources to the most important programs in order to increase its operating efficiencies. The Company will instead focus on its second-generation HCV-entry inhibitor portfolio and anticipates selection of a new development candidate in 2010.
You May Also Be Interested In
- Mylan (MYL) Unit Launches Generic Viramune Tabs
- Pluristem (PSTI) CEO Aberman Sends Letter to Shareholders;
- Baird Reiterates a 'Neutral' on Onyx Pharmaceuticals (ONXX); Nexavar Miss Not Real Issue; Kyprolis Remains Focus
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
